ZenaTech Seeks Shareholder Approval for Highly Dilutive Related-Party Asset Acquisition and Substantial CEO Equity Grants

summarizeSummary

ZenaTech, Inc. is seeking shareholder approval for a new CEO employment agreement with substantial equity grants and a highly dilutive $33 million related-party asset acquisition, significantly increasing the CEO's voting control.

check_boxKey Events

• New CEO Employment Agreement

  Dr. Shaun Passley's new 10-year agreement includes an annual salary of $350,000 and initial equity grants valued at $5.25 million (25,000 Super Voting Shares and 1.5 million Preferred Shares).

• Performance-Based Equity Grants

  The CEO is eligible for additional equity grants and salary increases for every $10 million in annual gross revenue above a $10 million baseline.

• Highly Dilutive Related-Party Asset Acquisition

  ZenaTech proposes to acquire various technology assets from Epazz, Inc., a company controlled by Dr. Passley, for $33 million in Preferred and Super Voting Shares.

• Significant Shareholder Dilution

  The combined initial equity grants and asset acquisition represent a substantial issuance of new shares, leading to significant dilution for existing shareholders, totaling approximately 28.5% of the current market capitalization.

auto_awesomeAnalysis

This 6-K filing outlines critical proposals for ZenaTech, Inc. that, if approved, will have a profound negative impact on existing shareholders. The new CEO employment agreement grants Dr. Shaun Passley a substantial compensation package, including an increased salary and initial equity valued at $5.25 million, with further performance-based grants. More significantly, the company plans a $33 million acquisition of assets from Epazz, Inc., a company controlled by Dr. Passley, to be paid entirely in Preferred and Super Voting Shares. These transactions collectively represent a highly dilutive event, with the total initial share issuance equating to approximately 28.5% of the company's current market capitalization. While the company cites benefits from the asset acquisition, the related-party nature of the transaction raises significant governance concerns regarding fair valuation and potential conflicts of interest. Furthermore, these issuances will substantially increase Dr. Passley's already dominant voting control, potentially entrenching management and limiting minority shareholder influence. Investors should be aware of the significant dilution and governance implications of these proposals.